Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from RemeGen Co. Ltd. Class H ( (HK:9995) ).
RemeGen Co., Ltd. announced its estimated financial results for 2024, projecting a revenue increase of approximately 58% compared to 2023. Despite still expecting a net loss, the company reports a reduction in losses due to increased R&D investments and growing sales from its key products, indicating an improvement in its financial performance.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the research and development of innovative drugs, and its primary products include telitacicept and disitamab vedotin.
YTD Price Performance: -14.03%
Average Trading Volume: 2,334,330
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$12.38B
For an in-depth examination of 9995 stock, go to TipRanks’ Stock Analysis page.